It has recently been described as a safe alternative to gold therapy, with a much lower incidence of toxicity. Several adverse reactions have been associated with sulphasalazine and are almost always reversible with discontinuation of the drug.7
Hepatotoxicity has not previously been described in RA patients receiving SASP. This report describes hepatotoxicity, as indicated by raised serum alkaline phosphatase and aspartate transaminase levels, in two patients with RA treated with sulphasalazine. Paticnt 2 patients was detected early and fell again after withdrawal of the drug. but hepatotoxicity may progress to acute focal hepatocellular necrosis' or chronic granulomatous hepatitis. 16 The nausea, vomiting, flatulence, and abdominal pain experienced by patient 1 are well recognised early side effects of SASP due to the sulphonamide component and may not be directly associated with the rise in liver enzymes.
The mechanism of SASP associated reactions in these two patients is probably due to a hypersensitivity reaction resulting from the sulphapyridine moiety of SASP.'2 6 and it may progress to cholestatic jaundice and hepatic injury. Thus early hepatotoxicity should be added to the list of possible complications of SASP thlerapy in RA. It is important to monitor liver function to detect and reverse this adverse reaction promptly. 
